Form 4 for KYMR Kymera Therapeutics, Inc.
Accepted 2026-06-03 07:30:03 ET · period of report 2026-06-02 · accession 0001193125-26-254589 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2026-06-03 07:30 | 2026-06-02 | KYMR | Jacobs Bruce N. | CFO | M - OptEx | $2.08 | +12.7K | 260.2K | +5% | +$26.3K |
| D | 2026-06-03 07:30 | 2026-06-02 | KYMR | Jacobs Bruce N. | CFO | M - OptEx | $0.00 | -12.7K | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-06-02 | M | A | 12,653 | $2.08 | 260,241 | D | — | — | |
| 2 | Derivative | Stock Option (Right to Buy) | 2026-06-02 | M | D | 12,653 | $0.00 | 0 | D | $2.08 · — to 2029-08-28 | 12,653 Common Stock | (F1) The shares underlying this stock option are fully vested and exercisable. |